zhpsЖурнал прикладной спектроскопииZhurnal Prikladnoii Spektroskopii0514-7506B. I. Stepanov Institute of Physics of the National Academy of Scienceszhps-1543Research ArticleАННОТАЦИИ АНГЛОЯЗЫЧНЫХ СТАТЕЙABSTRACTS ENGLISH-LANGUAGE ARTICLESСпектрофотометрическое определение цефиксима посредством комплексообразования с сульфатом ванадилаSpectrophotometric Survey of Cefixime via Facile Complexation with Vanadyl SulfateJanR.JanR. 

Мансехра

Mansehra KPK

BashirN.BashirN.

Мансехра

Mansehra KPK

RaufN.RaufN.

Исламабад

Islamabad

naseemrauf@yahoo.comTahirS. S.TahirS. S.

Исламабад

Islamabad

FarooqM.FarooqM.

Исламабад

Islamabad

mfaruq752@gmail.comХазарский университетHazara UniversityПакистанский совет научных и промышленных исследований (PCSIR)Pakistan Council of Scientific and Industrial Research (PCSIR)202429042024912317317Copyright © Jan R., Bashir N., Rauf N., Tahir S.S., Farooq M., 20242024Jan R., Bashir N., Rauf N., Tahir S.S., Farooq M.Jan R., Bashir N., Rauf N., Tahir S.S., Farooq M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://zhps.ejournal.by/jour/article/view/1543

Описан точный и простой спектрофотометрический метод определения цефиксима в различных составах, основанный на комплексообразовании цефиксима с сульфатом ванадила в кислой среде. Продукт комплексообразования желтого цвета проявлял максимум поглощения 321 нм и подчинялся закону Бера при концентрации цефиксима 210−6—110−4 М. С использованием спектроскопических данных рассчитаны стандартное отклонение S = 6.5×10–5, предел обнаружения LOD = 1.96×10–4, предел количественного определения LOQ = 6.5×10−4 М и относительное стандартное отклонение RSD = 0.057%. Рассчитанная константа образования полученного комплекса 5.7×1016 показывает стабильность конечного комплекса.

Herein, an accurate and simple spectrophotometric method for investigating cefixime in different formulations is reported. The proposed method elaborates on the complexation of cefixime with vanadyl sulfate in acidic media. The yellow color complexation product manifested its maximum absorbance peak at around 321 nm, and obeyed Beer’s law in 210−6–110−4 M cefixime concentration. Obtained spectroscopic data were used to calculate standard deviation (S), limit of detection (LOD), limit of quantification (LOQ), and relative standard deviation (RSD) as 6.5×10−5, 1.96×10−4, 6.5×10−4 M, and 0.057%, respectively. In addition, the formation constant associated with the complex obtained, calculated as 5.7×1016, indicates that the final complex was remarkably stable.

цефиксимсульфат ванадиласпектрофотометрический методантибиотикбета-лактамcefiximevanadyl sulfatespectrophotometric methodantibioticbeta-lactamWe are thankful to PCSIR Laboratories, Islamabad, and Hazara University, Mansehra, Pakistan, for their cooperation.ReferencesM. Ramalingam, V. Sethuraman, N. Sundaraganesan, Spectrochim. Acta A: Mol. and Biomol. Spectrosc., 78, No. 2, 660–669 (2011).M. Ramalingam, V. Sethuraman, N. Sundaraganesan, Spectrochim. Acta A: Mol. and Biomol. Spectrosc., 78, No. 2, 660–669 (2011).J. Shah, M. Rasul Jan, M. Yousaf, J. Appl. Spectrosc., 83, No. 2, 248–253 (2016).J. Shah, M. Rasul Jan, M. Yousaf, J. Appl. Spectrosc., 83, No. 2, 248–253 (2016).A. Kumar, et al., Der Pharma Chemica, 3, No. 4, 279–291 (2011).A. Kumar, et al., Der Pharma Chemica, 3, No. 4, 279–291 (2011).J. Bajwa, et al., Spectrochim. Acta A: Mol. and Biomol. Spectrosc., 238, 118446 (2020).J. Bajwa, et al., Spectrochim. Acta A: Mol. and Biomol. Spectrosc., 238, 118446 (2020).D. Adam, U. Hostalek, K. Tröster, Infection, 23, No. 2, S83–S86 (1995).D. Adam, U. Hostalek, K. Tröster, Infection, 23, No. 2, S83–S86 (1995).S. N. H. Azmi, et al., J. Pharm. Analysis, 3, No. 4, 248–256 (2013).S. N. H. Azmi, et al., J. Pharm. Analysis, 3, No. 4, 248–256 (2013).M. Dehghani, N. Nasirizadeh, M. E. Yazdanshenas, Mater. Sci. Eng. C, 96, 654–660 (2019).M. Dehghani, N. Nasirizadeh, M. E. Yazdanshenas, Mater. Sci. Eng. C, 96, 654–660 (2019).W. H. Organization, The Selection and Use of Essential Medicines, Rep. WHO Expert Committee, March 2011 (including the 17th WHO model list of essential medicines and the 3rd WHO model list of essential medicines for children), World Health Organization (2012).W. H. Organization, The Selection and Use of Essential Medicines, Rep. WHO Expert Committee, March 2011 (including the 17th WHO model list of essential medicines and the 3rd WHO model list of essential medicines for children), World Health Organization (2012).Z. Talebpour, et al., Sci. Pharm., 81, No. 2, 493–504 (2013).Z. Talebpour, et al., Sci. Pharm., 81, No. 2, 493–504 (2013).D. Zendelovska, T. Stafilov, P. Miloševski, Bull. Chemists and Technologists of Macedonia, 22, 39–45 (2003).D. Zendelovska, T. Stafilov, P. Miloševski, Bull. Chemists and Technologists of Macedonia, 22, 39–45 (2003).K. S. Khandagle, et al., Int. J. Pharm. Pharm. Sci., 3, No. 1, 46–48 (2011).K. S. Khandagle, et al., Int. J. Pharm. Pharm. Sci., 3, No. 1, 46–48 (2011).A. Solangi, et al., Acta Chromatographica, 19, 81 (2007).A. Solangi, et al., Acta Chromatographica, 19, 81 (2007).Z. Masoudyfar, S. Elhami, Spectrochim. Acta A: Mol. and Biomol. Spectrosc., 211, 234–238 (2019).Z. Masoudyfar, S. Elhami, Spectrochim. Acta A: Mol. and Biomol. Spectrosc., 211, 234–238 (2019).J. Shah, M. R. Jan, S. Shah, J. Fluoresc., 21, No. 2, 579–585 (2011).J. Shah, M. R. Jan, S. Shah, J. Fluoresc., 21, No. 2, 579–585 (2011).D. Tarasov, et al., J. Appl. Spectrosc., 89, No. 5, 821–828 (2022).D. Tarasov, et al., J. Appl. Spectrosc., 89, No. 5, 821–828 (2022).K. Roopa, et al., J. Appl. Spectrosc., 89, No. 4, 809–818 (2022).K. Roopa, et al., J. Appl. Spectrosc., 89, No. 4, 809–818 (2022).N. Bukhari, et al., Sensor Lett., 8, No. 2, 280–284 (2010).N. Bukhari, et al., Sensor Lett., 8, No. 2, 280–284 (2010).G.-K. Liu, H. Zheng, J.-L. Lu, Trends Environ. Analyt. Chem., 16, 16–23 (2017).G.-K. Liu, H. Zheng, J.-L. Lu, Trends Environ. Analyt. Chem., 16, 16–23 (2017).A. A. Ramadan, H. Mandil, M. Dahhan, Int. J. Pharm. Pharm. Sci., 5, No. 1, 428–433 (2013).A. A. Ramadan, H. Mandil, M. Dahhan, Int. J. Pharm. Pharm. Sci., 5, No. 1, 428–433 (2013).S. Dhahir, N. Mohammed, The Iraq. J. Agric. Sci., 50, No. 4, 1390–1404 (2019).S. Dhahir, N. Mohammed, The Iraq. J. Agric. Sci., 50, No. 4, 1390–1404 (2019).M. Rubel, S. Akij, S. Islam, Edelweiss Pharma Analytic Acta (2019), doi: 10.33805/2689-9477.104.M. Rubel, S. Akij, S. Islam, Edelweiss Pharma Analytic Acta (2019), doi: 10.33805/2689-9477.104.U. I. Jahan, M. S. Islam, J. Mol. Pharm. and Regulatory Affairs, 1, No. 2, 1–6 (2019).U. I. Jahan, M. S. Islam, J. Mol. Pharm. and Regulatory Affairs, 1, No. 2, 1–6 (2019).

The authors declare that there are no conflicts of interest present.